Peter Sondermann Email & Phone Number

Berlin, Berlin, DE

• Set-up, review and challenge of scientific concepts, composition of preclinical and CMC development plans, conduction of market and competition analyses
• Generation of business and project plans including the underlying strategy

Tokyo, JP, JP

• Integration of SuppreMol's research projects into the Shire organization
• Scientific support for SM101 (now SHP652) currently in Phase II studies

Illinois, US

• First contact point for all scientific aspects of SuppreMol’s product candidates
• Continuation of the development of SuppreMol’s antibody projects from preclinical to clinical state
• Scientific evaluation of projects for in-licensing
• Establishment and improvement of work and communication streams between SuppreMol and Baxalta

Martinsried, Bavaria, DE

• Responsible for the development of biotherapeutics for treating autoimmune diseases and leading of the R&D unit
• Securing over $8M research budget by grant applications
• Business Development with the CEO leading to the sale of SuppreMol GmbH to Baxter/Baxalta (March 2015)

Martinsried, Bavaria, DE

Analysis and proposal of scientific concepts for the company

Switzerland 🇨🇭, CH

Development and conduction of analytics for innovative protein therapeutics, several patent applications

Development and conduction of analytics for innovative protein therapeutics, specifically antibodies, Fc engineering, generation of cell lines and assays to measure the potency of mAbs (ADCC, CDC)

Martinsried, Bayern, DE

Planning and conduction of protein crystallography projects, that resulted in writing of publications and patent applications

Martinsried, Bayern, DE

Set-up of a bacterial expression system and a methodology that allowed the generation of active, homogeneous proteins by refolding for biochemical and structure analysis